American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
AVAI BIO, INC.
$0.20
+9.72%
OTC: AVAI · 15-min delayed
$276.3KRevenue · FY2023
-$1.1MNet income
AVAIOTC
About AVAI BIO, INC.
AVAI BIO INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2023
- $276.3K
- Net income
- -$1.1M
- Total assets
- $224.7K
Source: SEC EDGAR · updated Jun 7, 2026
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $1.1M in FY2023.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AVAI BIO, INC..
Write a review
Newsroom
News about AVAI BIO, INC.
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
Scalable Biotech Manufacturing Unlocks a $14B Market
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
News & sentiment via Polygon.io
Explore
Browse all →
